Dr. David Gunn received his B.S. in Chemistry (1990) from Loyola University of Chicago. He continued his studies while working as a Research Associate at Abbott Laboratories. After several years, he moved to Connecticut and joined the Medicinal Chemistry Department at Bayer Healthcare and The Institute for Diabetes Discovery (IDD). As a Principal Investigator at Bayer and IDD he contributed to several clinical candidate drug selections (Sorafenib, Lidorestat and Pozanicline) as well as expertise in several therapeutic areas, including oncology, metabolic diseases and inflammation. His publications can be found in Current Topics in Medicinal Chemistry, Journal of Medicinal Chemistry, Synthesis.
After his tenure in the Pharmaceutical Industry, he utilized his technical knowledge to become a thought leader in Microwave Chemistry including microwave batch/flow synthesis and microwave digestion for the analysis of trace metals with Milestone Inc. He has now returned to synthetic challenges by staying in enabling technologies as a Sales and Support Manager for ThalesNano Inc. with a focus on Microreactor flow synthesis. He added his experience by maintaining microwave and flow chemistry resource blogs as a source of information on current advancements in the area of enabling chemical technologies: totallymicrowave.wordpress.com and synthflow.wordpress.com.
Enabling chemistry technologies; Microwave synthesis; Continuous-Flow synthesis; Green chemistry; Multi-component flow synthesis; Alkaloid total synthesis; Undergraduate education enabling technologies.